Physician profile
Anna Magliolo
NPI 1548624323
$548.88
in general payments reported to CMS, 2019-2025
13 companies · $33.71 in 2025
The $33.71 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $106 · 2021: $238 · 2022: $23.79 · 2023: $92.56 · 2024: $54.94 · 2025: $33.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $181.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $143.24 | 2023-2025 | |
| Glaxosmithkline, LLC. | $108.71 | 2020-2022 | |
| Adlon Therapeutics L.P. | $43.85 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.68 | 2020-2021 | |
| Corium, LLC | $37.97 | 2023-2025 | Azstarys |
| Tris Pharma INC | $34.70 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $26.45 | 2021 | |
| Merck Sharp & Dohme LLC | $25.54 | 2020-2021 | |
| Genentech USA, INC. | $24.18 | 2020 | |
| Neos Therapeutics, LP | $19.52 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.56 | 2021 | |
| Sanofi Pasteur INC. | $14.27 | 2021 | |
| Seqirus USA INC | $14.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Magliolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.